Abstracts Archive - Page 2168 of 2425 - ACR Meeting Abstracts

Abstract Number: 1251 • 2013 ACR/ARHP Annual Meeting
Collagen Antibodies Induce Pain-Like Behavior In Mice Without Signs Of Inflammation
Gustaf Wigerblad¹, Katalin Sandor¹, Kutty Selva Nandakumar², Rikard Holmdahl³ and Camilla Svensson¹, ¹Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, ²Department of Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden, ³Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Collagen Antibody Induced Arthritis (CAIA) is a mouse model of rheumatoid arthritis (RA). It is induced by injection of a cocktail of monoclonal antibodies…
Abstract Number: 1252 • 2013 ACR/ARHP Annual Meeting
The Effect of Pretreatment With Resiniferatoxin On Dynamic Weight Bearing Measures and Evoked Pain Responses in An Acute Arthritis Murine Model
Mishal Abdullah¹, Christopher W. Dorman², Sandra Frizelle², Sonia C. Funkenbusch², Maren L. Mahowald³ and Hollis E. Krug⁴, ¹Rheumatology, University of Minnesota Medical School, Minneapolis, MN, ²Research, Minneapolis VA Health Care System, Minneapolis, MN, ³Medicine, University of Minnesota Medical School and Minneapolis VA Health Care System, Minneapolis, MN, ⁴Medicine, VA Health Care System, Minneapolis, MN
Background/Purpose: We have previously shown that activation of vanilloid receptors by intra-articular (IA) Capsaicin (CAP) injection normalizes Evoked Pain Scores (EPS) and Dynamic Weight Bearing…
Abstract Number: 1253 • 2013 ACR/ARHP Annual Meeting
Studies On The Relationship Between Intraplantar Carrageenan-Induced Bradykin B1 Receptor Messenger Ribonucleic Acid Expression and Oedema and Hyperalgesia In Rats: Effects Of Dexamethasone and a B1 Receptor Antagonist, BI-113823
Guy Kennett¹, Jessica Arlott¹, Phil Butler², Mike Comer¹, Andrew Clarkson², Alex Coulthard¹, Sean Lightowler¹, Rachel Upcott-Gill², Rebecca Upton¹, Louise Wray², Philipp Wabnitz³, Sven Kühnert³ and Simon Cruwys³, ¹Saretius Ltd, Reading, United Kingdom, ²Cyprotex Ltd, Macclesfield, United Kingdom, ³Grunenthal GmbH, Aachen, Germany
Background/Purpose: Kinins are a group of peptides formed in plasma and tissues in response to infection, tissue trauma or inflammation (inflamm) whose actions are mediated…
Abstract Number: 1254 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Antinuclear Antibodies In Schoolchildren Across Puberty and Possible Relationship With Musculoskeletal Pain. A Longitudinal Study
Francesca Sperotto¹, Sara Brachi², Mara Seguso³, Fabio Vittadello¹ and Francesco Zulian⁴, ¹Department of Pediatrics, University of Padua, Padua, Italy, ²Department of Pediatrics, University of Ferrara, Ferrara, Italy, ³Department of Laboratory Medicine, University of Padua, Padua, Italy, ⁴PRINTO, Genoa, Italy
Background/Purpose: Antinuclear antibodies (ANA) are frequently found in children with connective tissue diseases but can also be found in healthy individuals even in absence of…
Abstract Number: 1222 • 2013 ACR/ARHP Annual Meeting
Analysis Of Corelation Of Bone Mineral Density Of Spine With Other Sites In Ankylosing Spondylitis As Compared To Rheumatoid Arthritis and Control Populations
Janie Bruce¹ and Vikas Majithia^2,3, ¹Div of Rheumatology, University of Mississippi School of Medicine, Jackson, MS, ²Div of Rheumatology, University of Mississippi Medical Center, Jackson, MS, ³G.V. "Sonny" Montogomery VA Medical Center, Jackson, MS
Background/Purpose: Bone mineral density (BMD) at the 3 central sites usually correlates with each other but the effect of disease states on this correlation is…
Abstract Number: 1230 • 2013 ACR/ARHP Annual Meeting
Analysis Of Fracture Risk Assessment Score (FRAX) Correlation With Bone Mineral Density (BMD) In Males and Post-Menopausal Females
Vikas Majithia¹ and Khush Aujla², ¹Div of Rheumatology, University of Mississippi Medical Center, Jackson, MS, ²Division of Rheumatology, University of Mississippi School of Medicine, Jackson, MS
Background/Purpose: Fracture Risk Assessment Tool (FRAX) is a useful clinical tool for assessment of fracture risk and a major development in evaluation of osteoporosis. Its…
Abstract Number: 1214 • 2013 ACR/ARHP Annual Meeting
Resistant Or Recurrent Acute Pericarditis: A New Therapeutic Opportunity?
Claire Massardier¹, Claire Dauphin², Romain Eschalier², Jean-René Lusson² and Martin Soubrier³, ¹cardiology, CHU CLERMONT-FERRAND, Clermont-ferrand, Colombia, ²cardiology, CHU CLERMONT-FERRAND, Clermont-ferrand, France, ³Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France
Background/Purpose: The treatment of recurrent pericarditis relies on aspirin and/or non-steroidal anti-inflammatory drugs, as well as colchicine. Corticosteroid therapy, which is offered in resistant forms,…
Abstract Number: 1215 • 2013 ACR/ARHP Annual Meeting
Human Immunodeficiency Virus Infection and Fracture Risk-a Meta-analysis
Sian Yik Lim¹, Ana Marcella Rivas² and Kenneth Nugent³, ¹Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, ²Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, ³3601, Texas Tech University Health Sciences Center, Lubbock, TX
Background/Purpose: Human Immunodeficiency Virus (HIV) infection is associated with development of osteoporosis and decreased bone mineral density. However, studies have been inconclusive in whether this…
Abstract Number: 1216 • 2013 ACR/ARHP Annual Meeting
Risk Factors Associated With Fracture Occurrence Appear to Differ Between Distal Radius, Clinical Vertebral, and Hip Fractures in Japanese Patients With Rheumatoid Arthritis: A Prospective Observational Cohort Study
Kensuke Ochi¹, Takefumi Furuya¹, Yuki Go¹, Eisuke Inoue², Katsunori Ikari¹, Atsuo Taniguchi², Hisashi Yamanaka¹ and Shigeki Momohara², ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) are at high risk of developing fractures. Previously, utilizing data from our Institute of Rheumatology Rheumatoid Arthritis (IORRA) cohort…
Abstract Number: 1217 • 2013 ACR/ARHP Annual Meeting
Determination Of Vitamin D Level Prior To The Initiation Of Bisphosphonate Therapy
Chris T. Derk¹, Ruchika Patel², Rennie L. Rhee², Yiu Tak Leung¹, R. Michelle Koolaee², Shiv Sehra² and Ashwini Komarla³, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Vitamin D deficiency is under-recognized and in 18-35% of patients who do not respond to bisphosphonates, concurrent use of vitamin D 1000 units daily…
Abstract Number: 1218 • 2013 ACR/ARHP Annual Meeting
Incidence Of and Risk Factors For Clinical Fractures In Patients With Systemic Lupus Erythematosus and Matched Controls: A Population-Based Study In The United Kingdom
Irene Bultink¹, Nicholas Harvey², Arief Lalmohamed^3,4, Cyrus Cooper⁵, Willem Lems⁶, Tjeerd Van Staa^2,3,7 and Frank de Vries^3,4,8,9, ¹Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ²University of Southampton, MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom, ³Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, Netherlands, ⁴Clinical Pharmacy, University Medical Center Utrecht, Utrecht, Netherlands, ⁵NDORMS; MRC Lifecourse Epidemiology Unit, University of Oxford; Southampton General Hospital, Southampton, United Kingdom, ⁶Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁷Medicine and Helathcare Products Regulatory Agency, Clinical Practice Research Datalink, London, United Kingdom, ⁸Care and Public Health Research Institute, Maastricht, Netherlands, ⁹Clinical Pharmacy and Toxicology, Maastricht University Medical Centre, Maastricht, Netherlands
Background/Purpose: Systemic lupus erythematosus (SLE) has been associated with an increased risk of low bone mineral density and fractures. However, data on absolute fracture risk…
Abstract Number: 1219 • 2013 ACR/ARHP Annual Meeting
Phase 3 Fracture Trial Of Odanacatib For Osteoporosis – Baseline Characteristics and Study Design
Socrates Papapoulos¹, Henry G. Bone², David W. Dempster³, John Eisman⁴, Susan Greenspan⁵, Michael McClung⁶, Toshitaka Nakamura⁷, Joseph Shih⁸, Albert Leung⁹, Arthur Santora¹⁰, N. Verbruggen¹¹ and Antonio Lombardi¹², ¹Leiden University Medical Center, Leiden, Netherlands, ²Michigan Bone and Mineral Clinic, Detroit, MI, ³Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY, ⁴The Garvan Institute of Medical Research, Sydney, Australia, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶Oregon Osteoporosis Center, Portland, OR, ⁷University of Occupational & Environmental Health, Fukuoaka, Japan, ⁸Robert Wood Johnson Medical School, Piscataway, NJ, ⁹Clinical Research, Merck Sharp and Dohme Corp., Rahway, NJ, ¹⁰Merck Sharp & Dohme Corp., Whitehouse Station, NJ, ¹¹MSD Belgium, Brussels, Belgium, ¹²Merck Sharp and Dohme Corp., Rahway, NJ
Background/Purpose: Odanacatib is a selective and reversible inhibitor of cathepsin K; a collagenase secreted by osteoclasts, and is currently being evaluated for the treatment of…
Abstract Number: 1220 • 2013 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Characteristics and Fracture Risk: A Population-Based Study
Shreyasee Amin¹, Sherine E. Gabriel², Sara J. Achenbach³, Elizabeth J. Atkinson³, Terry M. Therneau³ and L. Joseph Melton III³, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: Women and men with rheumatoid arthritis [RA] are at increased risk for a fragility fracture [fx]. To help better target those in need of…
Abstract Number: 1221 • 2013 ACR/ARHP Annual Meeting
The Effects Of Hyperthyroidism On Bone Mineral Density At Different Sites- An Observational Case-Control Study
Christopher Varley¹, Alexander Oldroyd¹ and Marwan Bukhari², ¹Lancaster Medical School, Lancaster University, Lancaster, United Kingdom, ²Department of Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom
Background/Purpose: Hyperthyroidism has been described as a risk factor for poor bone health.1, 2 The FRAXTM tool has been used to identify the ten year…
Abstract Number: 1223 • 2013 ACR/ARHP Annual Meeting
Monitoring Osteoporosis Therapy: Can FRAX Help To Assess Success Or Failure In Achieving Treatment Goals?
Yasser El Miedany¹, Ahmed Elyassaki², Sally Youssef³, Annie Nasr⁴, Mohammed Hegazi⁵ and Ihab Ahmed⁶, ¹Rheumatology, Medway Hospital, Gillingham, United Kingdom, ²Rheumatology and Rehabilitation, Ain Shams University, Cairo, Egypt, ³Rheumatology & Rehabilitation, Ain Shams University, Cairo, Egypt, ⁴Radiology, Ain Shams University, Cairo, Egypt, ⁵Medicine, Al Adan Hospital, Kuwait, Kuwait, ⁶Medicine, Cairo University, Cairo, Egypt
Background/Purpose: 1. To determine whether FRAX can be used for monitoring patients receiving osteoporosis therapy and its clinical implications 2. Study the correlation between the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].